Amyloidosis cutis dyschromica represents a rare type of primary cutaneous amyloidosis with few reported cases worldwide. It is characterized by asymptomatic, generalized hyperpigmentation with intermingled hypopigmented macules without atrophy or telangiectasia. We report herein a 19-year-old female who developed this pigmentary abnormality at 4 years of age. Her aunt and great grandfather also had similar skin pigmentation. An unusual finding in our patient was the presence of papules in addition to characteristic macules. Amyloid deposits were shown histopathologically in both dyschromic macules and papules.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1600-0560.2011.01701.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Phenotype variability and therapeutic response to Patisiran in patients with hereditary transthyretin amyloidosis: a Belgian real-world experience.
Acta Clin Belg
February 2025
Department of Cardiology, Hôpital universitaire de Bruxelles, CUB Hôpital Erasme, Université libre de Bruxelles, Brussels, Belgium.
Introduction: Hereditary transthyretin amyloidosis (hATTRv) is a rare, genetic, adult-onset, multisystemic disorder which can affect diverse organs, including peripheral nerves, heart, kidneys, gastrointestinal tract, liver, skin and eyes. Currently, several disease-modifying treatments for hATTRv are available in Belgium including the TTR stabilizer tafamidis and TTR mRNA silencers patisiran and vutrisiran. Patisiran contains a small interfering RNA encapsulated into a lipid nanoparticle to deliver to hepatocytes, the main source of TTR protein production, thereby reducing TTR production.
View Article and Find Full Text PDFA systematic review and meta-analysis of treatments and outcomes of primary localized cutaneous amyloidosis.
Clin Exp Dermatol
February 2025
Department of Dermatology, the First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Background: Primary localized cutaneous amyloidosis (PLCA) is a skin-limited disorder characterized histologically by amyloid deposition in the papillary dermis. This study aimed to review current treatment strategies and provide an updated perspective on the treatment of PLCA.
Methods: We searched the PubMed, EMBASE and Cochrane Library databases for eligible studies.
The Efficacy of Off-Label Dupilumab in Cutaneous Amyloidosis.
J Cutan Med Surg
February 2025
Department of Dermatology and Skin Sciences, University of British Columbia, Vancouver, BC, Canada.
Eccrine syringofibroadenoma and amyloidosis cutis dyschromica: A new association.
Indian J Dermatol Venereol Leprol
January 2025
Department of Dermatology, Cairo University, Almanial, Cairo, Egypt.
POEMS Syndrome.
Presse Med
March 2025
Department of Hematology and Cellular Therapy, National Reference Center "AL Amyloidosis and Other Monoclonal Immunoglobulin Deposit Diseases, University Hospital of Limoges, Limoges, France; CNRS UMR-7276, INSERM U1262, Team 3 BioPIC of CRIBL, University of Limoges, Limoges, France.
POEMS syndrome (Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Protein, Skin changes) is a syndrome that involves a monoclonal B-cell proliferation, most often plasmacytic, and a variable number of manifestations listed or not in the acronym. These manifestations include sclerotic bone lesions, plasmacytic Castleman disease, papillary edema, peripheral edema, ascites, thrombocytosis and/or polycythemia, venous and/or arterial thrombosis, and renal, pulmonary, and cardiac impairments . Diagnosis is often delayed due to the rarity of this entity and its clinical polymorphism, which can mimic other neurological disorders.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!